You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR VESICARE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for VESICARE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00333112 ↗	A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.	Completed	Astellas Pharma Inc	Phase 4	2006-05-01	A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
NCT00368706 ↗	A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients	Completed	Astellas Pharma Inc	Phase 3	2006-09-01	To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
NCT00431041 ↗	Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)	Completed	Astellas Pharma Canada, Inc.	Phase 4	2006-12-01	The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00431041 ↗	Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)	Completed	Astellas Pharma Inc	Phase 4	2006-12-01	The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for VESICARE

Condition Name

Chart
Table

Condition Name for VESICARE
Intervention	Trials
Overactive Bladder	24
Urinary Bladder, Overactive	15
Urinary Incontinence	6
Urinary Bladder Overactive	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for VESICARE
Intervention	Trials
Urinary Bladder, Overactive	45
Enuresis	10
Urinary Incontinence	10
Urinary Incontinence, Urge	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for VESICARE

Trials by Country

Map
Table

Trials by Country for VESICARE
Location	Trials
United States	330
Canada	31
Germany	18
Hungary	15
United Kingdom	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for VESICARE
Location	Trials
California	15
Texas	13
Pennsylvania	13
Florida	13
North Carolina	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for VESICARE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for VESICARE
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	15
Phase 2/Phase 3	1
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for VESICARE
Clinical Trial Phase	Trials
Completed	50
Terminated	7
Unknown status	5
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VESICARE

Sponsor Name

Chart
Table

Sponsor Name for VESICARE
Sponsor	Trials
Astellas Pharma Inc	25
Astellas Pharma Europe B.V.	8
Astellas Pharma Korea, Inc.	6
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for VESICARE
Sponsor	Trials
Industry	52
Other	49
NIH	3
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.